Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 57Carcinoma, Non-Small-Cell Lung 46Ovarian Neoplasms 31Stomach Neoplasms 22Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Lung Neoplasms 18Neoplasm Metastasis 17Fallopian Tube Neoplasms 14Triple Negative Breast Neoplasms 13Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 10Colorectal Neoplasms 9Carcinoma, Ovarian Epithelial 9Melanoma 8Head and Neck Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Carcinoma, Renal Cell 6Adenocarcinoma of Lung 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Solid Tumors 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Recurrence 4Carcinoma, Transitional Cell 4

Interventions

eltrombopag 1durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cytarabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pathologic Complete Response × Paclitaxel × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡